IL5 and eosinophilic granulomatosis with polyangiitis: Extrapulmonary clinical presentation may be marked with involvement of cardiac, renal, gastrointestinal, neural system, skin and/or generalised constitutional symptoms.1,3 The armamentarium of EGPA treatment comprises mainly of corticosteroids and immunosuppressive agents with biological therapy being the newest option.3 Circulating interleukine-5 (IL-5) is increased in active EGPA and possibly interferes with production, maturation, activation, and tissue tropism of eosinophils.4 Anti-IL5 antibodies are under investigation for their potential therapeutic role in different disease settings.